| Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma (NCT05503667) | Shanghai Pulmonary Hospital, Shanghai, China | 2022-02-01 |
| A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy (NCT05511051) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-02-01 |
| Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients (NCT05298670) | German University in Cairo | 2022-02-01 |
| Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC (NCT05267366) | Qingdao Central Hospital | 2022-02-01 |
| CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (NCT07461831) | Beijing Tongren Hospital | 2022-02-01 |
| A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis (NCT05121480) | Evelo Biosciences, Inc. | 2022-01-31 |
| To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia (NCT05218642) | Suzhou Kintor Pharmaceutical Inc, | 2022-01-31 |
| Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (NCT05532059) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-01-31 |
| A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease (NCT05068284) | AbbVie | 2022-01-31 |
| Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma (NCT05034887) | National Cancer Center Hospital East | 2022-01-31 |
| Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (NCT05183854) | University of Utah | 2022-01-31 |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors (NCT05150691) | DualityBio Inc. | 2022-01-31 |
| A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer (NCT05203445) | Memorial Sloan Kettering Cancer Center | 2022-01-31 |
| Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (NCT04987307) | Amgen | 2022-01-31 |
| Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) (NCT04456023) | Novartis Pharmaceuticals | 2022-01-31 |
| Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study (NCT05262985) | Elizabeth Dudnik | 2022-01-31 |
| Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (NCT05084989) | Jiangsu Rec-Biotechnology Co., Ltd. | 2022-01-31 |
| Functional Sucrase Deficiency in Short Bowel Syndrome Patients With Intestinal Failure (NCT04604275) | University of Miami | 2022-01-31 |
| Gene Therapy Study for Children With CLN5 Batten Disease (NCT05228145) | Neurogene Inc. | 2022-01-31 |
| Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) (NCT04873869) | Neurocrine Biosciences | 2022-01-31 |
| Feasibility of the Adapted H-GRASP Feedback Program in the Chronic Phase Post Stroke. (NCT05227521) | KU Leuven | 2022-01-31 |
| A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer (NCT05130021) | Maxinovel Pty., Ltd. | 2022-01-31 |
| Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer (NCT05189067) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-01-31 |
| Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation (NCT05263947) | Tianjin Medical University Cancer Institute and Hospital | 2022-01-30 |
| A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease (NCT05626023) | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | 2022-01-30 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer (NCT05176223) | Mayo Clinic | 2022-01-30 |
| Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation (NCT05173805) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2022-01-30 |
| A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (NCT04933695) | Amgen | 2022-01-28 |
| Psilocybin Therapy for Depression in Bipolar II Disorder (NCT05065294) | University of California, San Francisco | 2022-01-28 |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944) | Children's Oncology Group | 2022-01-28 |
| Tamoxifen Versus Etoposide After First Recurrence in GBM Patients (NCT04765098) | AHS Cancer Control Alberta | 2022-01-28 |
| JT001 (VV116) for the Early Treatment of COVID-19 (NCT05242042) | Shanghai JunTop Biosciences Co., LTD | 2022-01-28 |
| A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels (NCT05161936) | Alnylam Pharmaceuticals | 2022-01-27 |
| Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma (NCT05251259) | AstraZeneca | 2022-01-27 |
| A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes (NCT04594941) | GE Healthcare | 2022-01-27 |
| Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (NCT04980833) | Novartis Pharmaceuticals | 2022-01-27 |
| NPI-002 Intravitreal Implant for the Delay of Cataract Progression (NCT05026632) | Nacuity Pharmaceuticals, Inc. | 2022-01-27 |
| Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia (NCT05139095) | Peking Union Medical College Hospital | 2022-01-27 |
| A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer (NCT05198804) | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 2022-01-27 |
| MBG453 in Lower Risk MDS (NCT04823624) | Massachusetts General Hospital | 2022-01-27 |
| ESP Block VS Intrathecal Opioid After Laparoscopic Colorectal Surgery (NCT05257941) | Indiana University | 2022-01-27 |
| A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma (NCT05156268) | Memorial Sloan Kettering Cancer Center | 2022-01-27 |
| Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM (NCT04941937) | Juan Du | 2022-01-27 |
| An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NCT04876313) | IRCCS San Raffaele | 2022-01-27 |
| GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients (NCT05191784) | Genexine, Inc. | 2022-01-26 |
| 9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (NCT05239182) | Anwaar Saeed | 2022-01-26 |
| A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis (NCT06085521) | Lynk Pharmaceuticals Co., Ltd | 2022-01-26 |
| Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study (NCT04987281) | M.D. Anderson Cancer Center | 2022-01-26 |
| Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer (NCT04919382) | Dwight Owen | 2022-01-26 |
| Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer (NCT05116085) | BeiGene | 2022-01-26 |
| Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain (NCT05177094) | Eli Lilly and Company | 2022-01-26 |
| Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer (NCT05149807) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-26 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents (NCT05334823) | Chongqing Precision Biotech Co., Ltd | 2022-01-26 |
| Charcoal in Lung Cancer Patients Undergoing TEMLA (NCT04928950) | Masonic Cancer Center, University of Minnesota | 2022-01-26 |
| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) (NCT05107128) | Supernus Pharmaceuticals, Inc. | 2022-01-26 |
| Clinical Trial Through Combined tACS Therapy in Patients With Mild Cognitive Impairment (NCT05291208) | Universidad del Desarrollo | 2022-01-26 |
| Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis (NCT05104853) | COUR Pharmaceutical Development Company, Inc. | 2022-01-25 |
| First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer (NCT05189457) | H. Lee Moffitt Cancer Center and Research Institute | 2022-01-25 |
| Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies (NCT04925544) | Stanford University | 2022-01-25 |
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection (NCT05121740) | PharmaMar | 2022-01-25 |
| Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (NCT05114746) | Novartis Pharmaceuticals | 2022-01-25 |
| NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder (NCT05136755) | China Medical University Hospital | 2022-01-25 |
| Efficacy and Safety of Liuwei Dihuang Pill Versus Placebo in Presbycusis With Shen (Kidney)-Yin Deficiency (NCT05125081) | Shanghai Jiao Tong University School of Medicine | 2022-01-25 |
| A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma (NCT05193214) | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 2022-01-25 |
| Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29 (NCT05253846) | Gruppo Oncologico del Nord-Ovest | 2022-01-25 |
| Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (NCT04929392) | City of Hope Medical Center | 2022-01-25 |
| A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder (NCT05067582) | Yamo Pharmaceuticals LLC | 2022-01-25 |
| Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN (NCT05260671) | Eye & ENT Hospital of Fudan University | 2022-01-25 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease (NCT05238597) | Aramis Biosciences, Inc. | 2022-01-25 |
| A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants (NCT05136677) | Bristol-Myers Squibb | 2022-01-25 |
| A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder (NCT05260541) | Praxis Precision Medicines | 2022-01-25 |
| Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia (NCT05199909) | Institute of Hematology & Blood Diseases Hospital, China | 2022-01-25 |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (NCT05098132) | Synthekine | 2022-01-25 |
| Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (NCT04564898) | Gruppo Oncologico del Nord-Ovest | 2022-01-25 |
| Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (NCT04802590) | The Lymphoma Academic Research Organisation | 2022-01-24 |
| Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (NCT04966676) | University Health Network, Toronto | 2022-01-24 |
| To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors (NCT05260385) | Beijing Konruns Pharmaceutical Co., Ltd. | 2022-01-24 |
| Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (NCT05203939) | Ocugen | 2022-01-24 |
| Enhancing the Effects of Alcohol Treatment With Lamotrigine (NCT04770493) | Brown University | 2022-01-24 |
| Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer (NCT05156060) | Natalie Lockney | 2022-01-24 |
| Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (NCT05175950) | Korea University Guro Hospital | 2022-01-24 |
| Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers (NCT05175404) | University Hospital, Ghent | 2022-01-24 |
| Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19 (NCT05210179) | Health Institutes of Turkey | 2022-01-24 |
| Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD (NCT04759703) | Massachusetts General Hospital | 2022-01-24 |
| A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia (NCT05171920) | CalciMedica, Inc. | 2022-01-24 |
| PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure (NCT05222035) | Sun Yat-sen University | 2022-01-24 |
| A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever (NCT04906980) | Janssen Research & Development, LLC | 2022-01-24 |
| Effectiveness of iPRF Injections in Temporomandibular Joints Degeneration Management (NCT05214924) | Wroclaw Medical University | 2022-01-24 |
| SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial (NCT05138575) | University of Pennsylvania | 2022-01-24 |
| A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 (NCT05197153) | Medigen Vaccine Biologics Corp. | 2022-01-22 |
| Local Anesthesia With Lidocaine or Articaine for Molars Affected by MIH (NCT05200884) | Latakia University | 2022-01-22 |
| A Study of AK112 in Advanced Malignant Tumors (NCT05214482) | Akeso | 2022-01-22 |
| A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors (NCT05173142) | Hutchison Medipharma Limited | 2022-01-22 |
| Efficacy, Safety and Pharmacokinetics Study of CPL207280 After 2-weeks Administration in Subjects With Type 2 Diabetes (NCT05248776) | Celon Pharma SA | 2022-01-21 |
| The Prehospital Administration of Normobaric Oxygen in Suspected Stroke (NCT05351073) | Capital Medical University | 2022-01-21 |
| ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer (NCT05182866) | Rakuten Medical, Inc. | 2022-01-21 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy (NCT05287386) | The First Affiliated Hospital of Xiamen University | 2022-01-21 |
| Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients (NCT05234190) | Quell Therapeutics Limited | 2022-01-21 |
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (NCT05309668) | AstraZeneca | 2022-01-21 |